P26
Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South AfricaXpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistanceLateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adultsUrine lateral flow lipoarabinomannan assay for diagnosing active tuberculosis in adults living with HIVDetection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications.Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysisAntiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methodsScreening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective studyRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirCost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South AfricaDevelopment of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studiesTuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsTuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis.HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response.Drug-resistant tuberculosis: time for visionary political leadership.BMC Medicine editorial board members on open access publishing.CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.Dengue hemorrhagic fever with fulminant hepatic failure in an immigrant returning to Bangladesh.Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited settingPrevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional studySupport and performance improvement for primary health care workers in low- and middle-income countries: a scoping review of intervention design and methods.Serological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa?Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa.Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking systemIs HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis.Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa.Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status.Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa.Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuriaRoutine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa?Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review.Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs.The eye as a model of ageing in translational research--molecular, epigenetic and clinical aspects.
P50
Q21261534-E0EAFCC5-F6C8-4C7E-A5F8-FBF82EC581E9Q22241307-74A75F97-3B09-48F6-9E6E-54BF5C164DEFQ24185754-632DC54D-DAD5-4747-91FD-FE5808C0232EQ24187533-3D4C76F6-1C2E-4E99-BB53-4298793F80B8Q26765388-D246FD1C-3039-4E6E-A8BA-B5C2F88A39D0Q26798435-BAB2D2BD-0A95-4C5A-A18F-D8F4055B4A89Q28478065-B8762688-2657-4074-8292-A1BE4DEFEDF7Q28479309-84B93E73-A458-42D2-BD94-AB7DB3C4FDDEQ28533242-17DC65C5-816D-4A96-A57A-66E5EBA82A0FQ28534733-FD8D1C5D-00A2-4CBB-AC44-7D8450F24088Q28743478-71F6B1C6-5162-443C-BBE0-E46E140AC324Q28749315-479ACAFF-7F6F-4D9C-965C-1716FF27B731Q30330412-88057E3D-390B-46C6-ABEF-B9C9F1C7251FQ30397119-4112B34A-DDE5-442D-A448-F936452CB441Q30428762-A4EB5F9A-B35A-4F38-A83B-2392878EF314Q30486635-14B342DA-1550-4B60-9EC0-5DDEFA9E208AQ33237178-3CAB5ECA-018D-4498-BBB8-AF3BA433E90BQ33284948-38836D9B-A149-4AE4-AE9C-DCD936B72CFBQ33348729-C3881A5D-D362-415D-B87E-B6825A2B3FACQ33349204-57D4B442-F493-4580-A77B-5B23AEB11B9FQ33506198-013CE821-D454-443B-9BF3-C0992227DF14Q33589844-8297BF87-05BE-469A-BB37-4A3998AE1981Q33743476-E989A8DC-575D-4657-8B1E-BF4FB7AE0731Q33745099-3E03F773-506F-48BD-ABD1-AD86ECEDBE75Q33746982-9DD1EAC3-07CE-43DD-B73B-3F4E086D7342Q33854505-C9405E30-E548-493F-9C52-C62C384CC4A6Q33871884-619EF6AB-0A46-4BCC-8ED8-D1065F6EEF48Q33920318-9037FD32-F768-4DEE-9968-072B7A8B1125Q33975232-FB0A24B6-D593-4B36-AE33-B75F18A84118Q34034880-D35651A4-14C6-4BA4-A224-16B5E16E2B67Q34039494-DA9D8F69-FFF7-483E-BE5F-C8357631C679Q34053275-3EFF0076-DC2D-4D3D-9549-BA20E580C689Q34138223-CAC438F7-5732-4467-AC08-8619DE9DEAF4Q34170017-C8DA078E-00BF-4A7E-B846-BECBD0A96B14Q34173643-B18AB77E-BFCA-4708-9931-DC7267C4E647Q34203298-F0C2AB87-C5A8-4DD2-A3D1-A9FE66773AB2Q34222186-C5472172-53C2-4401-BE3C-FDC141A2A105Q34247819-657EA0A9-F9E0-4204-A40F-4AF87BB97ED3Q34266001-3E06418A-1D15-4A7D-9852-041E844A9BBEQ34320001-61665611-0279-42BC-8261-334A848E40A0
P50
description
Academic who researched tuberculosis among AIDS sufferers
@en
académicu británicu (1966–2016)
@ast
name
Stephen Lawn
@ast
Stephen Lawn
@ca
Stephen Lawn
@en
Stephen Lawn
@es
Stephen Lawn
@fr
Stephen Lawn
@sl
Stephen Lawn
@sq
type
label
Stephen Lawn
@ast
Stephen Lawn
@ca
Stephen Lawn
@en
Stephen Lawn
@es
Stephen Lawn
@fr
Stephen Lawn
@sl
Stephen Lawn
@sq
altLabel
Stephen D Lawn
@en
Stephen D. Lawn
@en
prefLabel
Stephen Lawn
@ast
Stephen Lawn
@ca
Stephen Lawn
@en
Stephen Lawn
@es
Stephen Lawn
@fr
Stephen Lawn
@sl
Stephen Lawn
@sq
P106
P166
P19
P1960
pv4zcdzaiR4C
P20
P21
P26
P2941
stephen-david-lawn
P31
P509
P569
1966-03-13T00:00:00Z
P570
2016-09-23T00:00:00Z